Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated by Analysts at StockNews.com

Posted by Lisa Durand on Nov 14th, 2024

StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH – Free Report) in a research report report published on Wednesday. The brokerage issued a hold rating on the stock.

Separately, Alliance Global Partners cut their price objective on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a report on Wednesday, August 14th.

Read Our Latest Stock Analysis on AWH

Aspira Women’s Health Price Performance

Shares of NASDAQ:AWH opened at $0.82 on Wednesday. The business’s 50-day moving average is $0.86 and its 200 day moving average is $1.44. Aspira Women’s Health has a 1 year low of $0.74 and a 1 year high of $5.65. The firm has a market capitalization of $13.17 million, a P/E ratio of -0.57 and a beta of 1.44.

Aspira Women’s Health (NASDAQ:AWH – Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. The firm had revenue of $2.42 million during the quarter, compared to analyst estimates of $2.60 million. During the same period in the prior year, the company posted ($0.28) earnings per share. On average, analysts expect that Aspira Women’s Health will post -1.26 EPS for the current year.

Institutional Trading of Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. grew its position in Aspira Women’s Health Inc. (NASDAQ:AWH – Free Report) by 88.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 236,396 shares of the company’s stock after acquiring an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned about 1.90% of Aspira Women’s Health worth $352,000 as of its most recent SEC filing. 12.19% of the stock is currently owned by institutional investors.

About Aspira Women’s Health

(Get Free Report)

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.